Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion Biotech已與默沙東簽署一項選擇權和許可協議，涉及兩個臨床前階段的疫苗候選者，默沙東將支付$320萬的預付款，並且如果默沙東行使其對其中一個或兩個候選者的許可選擇權，到2025年最多可支付$1000萬。
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product
Evaxion生物科技已與默沙東簽訂了一項期權和許可協議，涉及兩個臨床前生物-疫苗候選者，首付款爲320萬美元，2025年默沙東行使其許可期權時，可達到1000萬美元，每種產品的里程碑支付可高達59200萬美元
Under the terms of the agreement, Evaxion has granted MSD an option to exclusively license Evaxion's preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea and EVX-B3 targets an undisclosed infectious agent.
根據協議條款，Evaxion已授予默克一個獨家許可期權，以獨家許可Evaxion的臨床前疫苗候選者EVX-B2和EVX-B3。 EVX-B2是一種基於蛋白質的淋病候選者，而EVX-B3針對一種未透露的傳染病原體。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。